Argent Trust Co Buys Shares of 4,617 Boston Scientific Co. (NYSE:BSX)

Argent Trust Co bought a new stake in Boston Scientific Co. (NYSE:BSX – Get Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 4,617 shares of the medical equipment provider’s stock, valued at approximately $214,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Montag A & Associates Inc. increased its position in Boston Scientific by 8.5% during the 4th quarter. Montag A & Associates Inc. now owns 2,712 shares of the medical equipment provider’s stock worth $125,000 after purchasing an additional 212 shares in the last quarter. Childress Capital Advisors LLC increased its position in Boston Scientific by 3.5% during the 4th quarter. Childress Capital Advisors LLC now owns 6,201 shares of the medical equipment provider’s stock worth $287,000 after purchasing an additional 212 shares in the last quarter. Hazlett Burt & Watson Inc. increased its position in Boston Scientific by 56.7% during the 4th quarter. Hazlett Burt & Watson Inc. now owns 636 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 230 shares in the last quarter. Dorsey & Whitney Trust CO LLC increased its position in Boston Scientific by 3.2% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 9,473 shares of the medical equipment provider’s stock worth $433,000 after purchasing an additional 291 shares in the last quarter. Finally, Parkside Financial Bank & Trust increased its position in Boston Scientific by 20.6% during the 1st quarter. Parkside Financial Bank & Trust now owns 1,793 shares of the medical equipment provider’s stock worth $79,000 after purchasing an additional 306 shares in the last quarter. Institutional investors and hedge funds own 90.23% of the company’s stock.

Insider Activity

In other news, EVP Joseph Michael Fitzgerald sold 63,339 shares of the stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $53.60, for a total transaction of $3,394,970.40. Following the completion of the transaction, the executive vice president now directly owns 213,859 shares in the company, valued at approximately $11,462,842.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CFO Daniel J. Brennan sold 75,610 shares of the company’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $46.64, for a total transaction of $3,526,450.40. Following the sale, the chief financial officer now directly owns 255,958 shares of the company’s stock, valued at approximately $11,937,881.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 63,339 shares of the stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $53.60, for a total value of $3,394,970.40. Following the completion of the sale, the executive vice president now directly owns 213,859 shares in the company, valued at $11,462,842.40. The disclosure for this sale can be found here. In the last three months, insiders sold 259,627 shares of company stock worth $13,157,519. 0.71% of the stock is currently owned by insiders.

Boston Scientific Stock Down 0.8 %

NYSE BSX opened at $51.54 on Friday. The stock has a market cap of $72.16 billion, a PE ratio of 87.36, a P/E/G ratio of 2.32 and a beta of 0.80. The company has a quick ratio of 0.89, a current ratio of 1.40 and a debt-to-equity ratio of 0.47. The business has a 50 day moving average price of $51.28 and a two-hundred day moving average price of $47.80. Boston Scientific Co. has a fifty-two week low of $34.98 and a fifty-two week high of $54.17.

Boston Scientific (NYSE:BSX – Get Rating) last released its earnings results on Wednesday, April 26th. The medical equipment provider reported $0.47 EPS for the quarter, beating the consensus estimate of $0.43 by $0.04. The company had revenue of $3.39 billion during the quarter, compared to analysts’ expectations of $3.16 billion. Boston Scientific had a return on equity of 14.57% and a net margin of 6.91%. The business’s revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.39 EPS. As a group, sell-side analysts predict that Boston Scientific Co. will post 1.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent research reports. UBS Group assumed coverage on Boston Scientific in a research report on Tuesday, March 28th. They set a “buy” rating and a $57.00 price objective for the company. Royal Bank of Canada lifted their price target on Boston Scientific from $53.00 to $56.00 in a report on Thursday, April 27th. BTIG Research lifted their price target on Boston Scientific from $53.00 to $54.00 and gave the company a “buy” rating in a report on Monday, April 17th. Argus lifted their price target on Boston Scientific from $50.00 to $55.00 in a report on Friday, February 17th. Finally, Mizuho lifted their price target on Boston Scientific from $52.00 to $56.00 in a report on Tuesday, April 18th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $53.89.

About Boston Scientific

(Get Rating)

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Urology and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions.